A new oral drug for advanced solid tumors that have not responded to other treatments
Part of Cancer clinical trials.
This trial tests a new oral drug (DAT-1604) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if it is safe, how the body processes it, and whether it can shrink or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Has advanced or metastatic solid tumor that has not responded to standard treatment or has no standard treatment.
- Can provide a tumor tissue sample (either from a previous biopsy or willing to undergo a new one).
- Able to perform daily activities independently (ECOG 0 or 1).
- Must have completed prior cancer treatments at least 21 days or 5 half-lives ago (whichever is shorter) and recovered from side effects.
- Adequate organ function (blood counts, kidney, liver) as determined by lab tests.
- No ongoing lung disease or certain heart rhythm issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This study tests an experimental pill (DAT-2645) for people with advanced or metastatic solid tumors that have DNA repair problems, such as BRCA gene mutations. The drug targets a repair mechanism that these cancer cells need, potentially slowing or stopping their growth.
This trial tests an experimental drug, BA1203, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and whether it can help shrink tumors.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.